Advertisement
Canada markets open in 8 hours

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7304
    +0.0006 (+0.09%)
     

  • CRUDE OIL

    82.93
    +0.12 (+0.14%)
     

  • Bitcoin CAD

    87,703.84
    -3,790.84 (-4.14%)
     

  • CMC Crypto 200

    1,387.49
    -36.61 (-2.57%)
     

  • GOLD FUTURES

    2,329.30
    -9.10 (-0.39%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,426.50
    -238.00 (-1.35%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    37,659.30
    -800.78 (-2.08%)
     

  • CAD/EUR

    0.6818
    -0.0001 (-0.01%)
     

Today’s Research Reports on Stocks to Watch: Dynavax Technologies and Puma Biotechnology

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / November 13, 2017 / Shares of Dynavax soared almost 18% in pre-market trading on Friday after the company announced its Hepislav-B vaccine for Hepatitis B was approved by the FDA. Shares of Puma Biotech dropped almost 20% on the other hand, despite the company posting strong quarterly results that included its Nerlynx breast cancer treatment.

RDI Initiates Coverage on:

Dynavax Technologies Corporation
https://rdinvesting.com/news/?ticker=DVAX

Puma Biotechnology, Inc.
https://rdinvesting.com/news/?ticker=PBYI

Dynavax Technologies Corporation shares closed up 1% on Friday with nearly 10 million shares traded. Shares skyrocketed in premarket trading before retracing after the company announced that its hepatitis B vaccine, Hepislav-B, was approved by the FDA. Traders were excited as this is the first hepatitis B vaccine in the United States in many years that has just two doses over a month. Other vaccines require three doses over six months. According to the company, it is expected to launch in the first quarter of 2018. According to RBC Capital Markets analyst Matthew Eckler. "Given Hepislav's superior efficacy and convenience profile, we continue to see potential to grow the current hep B vaccine market (~$270 M) through increased compliance, premium pricing and the capture of adult diabetic population, resulting in $300M projected peak revenue."

ADVERTISEMENT

Access RDI's Dynavax Technologies Corporation Research Report at:
https://rdinvesting.com/news/?ticker=DVAX

Puma Biotechnology, Inc. shares closed down nearly 19% on Friday with almost 5.7 million shares traded. The stock was one of the biggest decliners on the NASDAQ board that day, even hitting a two month low, despite the company beating estimates in its third-quarter report. For the quarter, the company reported a net loss of $77.2 million, or $2.07 a share. EPS, adjusted for one-time items, was a loss of $1.36 a share. Revenue was $6.1 million and the company's first and only commercial product to date, Nerlynx, was included. The maintenance treatment is used to treat breast cancer and was approved by the FDA in July. It brought in $6.1 million in sales for the quarter, ahead of the expectation of in between $3 million and $4 million. Wall Street was also waiting for an EPS loss of $2.06 a share and revenue of $4.1 billion. According to Leerink analyst Michael Schmidt says all the launch metrics "point in the right direction." According to RBC analyst Matthew Eckler, he projects Nerlynx pulling in $20 million in the fourth quarter and $26 million in 2017.

Access RDI's Puma Biotechnology, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=PBYI

Our Actionable Research on Dynavax Technologies Corporation (NASDAQ: DVAX) and Puma Biotechnology, Inc. (NASDAQ: PBYI) be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com